Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Patricia Dauer
Observed name:
P. Dauer
Institution:
Agendia (United States)
Observed institutions:
University of Minnesota,
Endeavor Health,
University of Miami,
University of Chicago,
Sylvester Comprehensive Cancer Center,
Agendia (United States)
show all 6
ORCID:
0000-0002-8374-5512
Observed ORCID:
0000-0002-8374-5512
OpenAlex ID:
A5059089028
Opioid-induced gut microbial disruption and bile dysregulation leads to gut barrier compromise and sustained systemic inflammation
2016
·
S. Banerjee
, G. Sindberg
, et al.
·
Mucosal Immunology
·
271
PDF
Preeclampsia pathophysiology and adverse outcomes during pregnancy and postpartum
2023
·
Courtney Bisson
, Sydney Dautel
, et al.
·
Frontiers in Medicine
·
161
PDF
Microenvironment in determining chemo-resistance in pancreatic cancer: Neighborhood matters
2016
·
Patricia Dauer
, Alice Nomura
, et al.
·
Pancreatology
·
154
ER stress sensor, glucose regulatory protein 78 (GRP78) regulates redox status in pancreatic cancer thereby maintaining “stemness”
2019
·
Patricia Dauer
, Nikita S. Sharma
, et al.
·
Cell Death and Disease
·
124
PDF
Inactivation of Cancer-Associated-Fibroblasts Disrupts Oncogenic Signaling in Pancreatic Cancer Cells and Promotes Its Regression
2017
·
Patricia Dauer
, Xianda Zhao
, et al.
·
Cancer Research
·
124
Inhibition of NF-kappa B pathway leads to deregulation of epithelial–mesenchymal transition and neural invasion in pancreatic cancer
2016
·
Alice Nomura
, Kaustav Majumder
, et al.
·
Laboratory Investigation
·
90
O-GlcNAc modification of Sox2 regulates self-renewal in pancreatic cancer by promoting its stability
2019
·
Nikita S Sharma
, Vineet K Gupta
, et al.
·
Theranostics
·
72
PDF
Metastasis and chemoresistance in CD133 expressing pancreatic cancer cells are dependent on their lipid raft integrity
2018
·
Vineet Kumar Gupta
, Nikita S. Sharma
, et al.
·
Cancer Letters
·
66
Microenvironment mediated alterations to metabolic pathways confer increased chemo-resistance in CD133+ tumor initiating cells
2016
·
Alice Nomura
, Patricia Dauer
, et al.
·
Oncotarget
·
58
PDF
New Roles for Glycogen in Tumor Progression
2019
·
Patricia Dauer
, Ernst Lengyel
·
Trends in cancer
·
56
NFκB-Mediated Invasiveness in CD133+ Pancreatic TICs Is Regulated by Autocrine and Paracrine Activation of IL1 Signaling
2017
·
Alice Nomura
, Vineet K. Gupta
, et al.
·
Molecular Cancer Research
·
55
Inhibition of hypoxic response decreases stemness and reduces tumorigenic signaling due to impaired assembly of HIF1 transcription complex in pancreatic cancer
2017
·
Olivia McGinn
, Vineet K. Gupta
, et al.
·
Scientific Reports
·
50
PDF
GRP 78‐mediated antioxidant response and ABC transporter activity confers chemoresistance to pancreatic cancer cells
2018
·
Patricia Dauer
, Nikita S. Sharma
, et al.
·
Molecular Oncology
·
47
PDF
Inhibition of Sp1 prevents ER homeostasis and causes cell death by lysosomal membrane permeabilization in pancreatic cancer
2017
·
Patricia Dauer
, Vineet K. Gupta
, et al.
·
Scientific Reports
·
35
PDF
Downregulation of Sp1 by Minnelide leads to decrease in HSP70 and decrease in tumor burden of gastric cancer
2017
·
Nivedita Arora
, Osama Alsaied
, et al.
·
PLoS ONE
·
30
PDF
Bioflavonoid luteolin prevents sFlt ‐1 release via HIF ‐1α inhibition in cultured human placenta
2023
·
Adrian C. Eddy
, Chun Yi Chiang
, et al.
·
The FASEB Journal
·
21
PDF
High concordance of 70‐gene recurrence risk signature and 80‐gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early‐stage breast cancer
2021
·
Jennifer A. Crozier
, Julie Barone
, et al.
·
Journal of Surgical Oncology
·
16
The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy
2023
·
Peter Blumencranz
, Mehran Habibi
, et al.
·
Annals of Surgical Oncology
·
11
PDF
Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy
2022
·
Pat W. Whitworth
, Peter D. Beitsch
, et al.
·
JCO Precision Oncology
·
8
Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancer
2022
·
James V. Pellicane
, Peter D. Beitsch
, et al.
·
Surgical Oncology
·
5
Abstract PD9-08: ImPrint immune signature in 10,000 early-stage breast cancer patients from the real-world FLEX database
2023
·
Adam M. Brufsky
, Midas Kuilman
, et al.
·
Cancer Research
·
3
Tu1964 Minnelide: A Novel Therapeutic Agent for Gastric Adenocarcinoma
2015
·
Nivedita Arora
, Osama Alsaied
, et al.
·
Gastroenterology
·
3
Whole transcriptomic analysis of HR+ breast cancer in Black women classified as basal-type by BluePrint.
2022
·
Sonya A. Reid
, Tuya Pal
, et al.
·
Journal of Clinical Oncology
·
2
Abstract PO1-28-01: MammaPrint and BluePrint identify racial disparities among women with HR+HER2- early-stage breast cancer
2024
·
Sonya Reid
, Xiao-Ou Shu
, et al.
·
Cancer Research
·
1
Abstract P5-09-02: Impact of neoadjuvant endocrine therapy on tumor transcriptome in patients with early-stage breast cancer from the FLEX trial
2023
·
Mehran Habibi
, Danijela Jelovac
, et al.
·
Cancer Research
·
1
Show more works
View as search
Works count:
54
Citation count:
1,465
H-index:
16
I10-index:
18
Year
Topic
Type
